Introduction {#Sec1}
============

Recent insights in sepsis pathology have led to the view that not the initial hyperinflammatory state, but rather a profoundly suppressed state of the immune system, also called immunoparalysis, accounts for the majority of sepsis-related deaths. Therefore, reconstitution of immunocompetence in sepsis is emerging as a promising therapeutic target to improve outcome. Bacille Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but exerts beneficial effects on other infectious diseases as well. These non-specific effects of BCG seem to be mediated by potentiation of adaptive immunity through heterologous effects, as well as epigenetic functional reprogramming of innate immune cells to an enhanced phenotype, a process described as \'trained immunity\', which has been shown *in vitro, ex vivo*, and in animal models. Therefore, BCG-vaccination could represent a novel therapeutic option to treat sepsis-induced immunoparalysis, although its immunomodulatory effects in humans *in vivo* have not yet been investigated. Furthermore, the live BCG vaccine presents a potential risk of disseminated disease in immunoparalyzed patients, which can be circumvented by inactivating the vaccine through gamma-irradiation.

Objectives {#Sec2}
==========

To determine the effects of gamma-irradiated BCG-vaccination on the *in vivo* innate immune responses induced by human endotoxemia. Also, to determine the effects of gamma-irradiated BCG-vaccination on *ex vivo* responsiveness of leukocytes to various inflammatory stimuli.

Methods {#Sec3}
=======

In a randomized double blind placebo-controlled study, healthy male volunteers were vaccinated with gamma-irradiated BCG (n = 10) or placebo (n = 10) and received 1 ng/kg lipopolysaccharide (LPS) intravenously on day 5 after vaccination to assess the *in vivo* immune response. Peripheral blood mononuclear cells were stimulated with various related and unrelated pathogens 5, 8 to 10, and 25 to 35 days after vaccination to assess *ex vivo* immune responses.

Results {#Sec4}
=======

LPS administration elicited a profound systemic immune response, characterized by increased levels of pro-and anti-inflammatory cytokines, hemodynamic changes, and flu-like symptoms. However, BCG neither modulated this *in vivo* immune response (Figure [1](#Fig1){ref-type="fig"}), nor *ex vivo* leukocyte responses at any time-point (Figure [2](#Fig2){ref-type="fig"}).Figure 1In the panels A and B, median values of pro-inflammatory cytokines TNF-α and Il-6 are depicted while in panel C median values of the anti-inflammatory cytokine IL-10 is shown (n = 10 per group). Panels D-F depict median ± interquartile range of area under curve (AUC) of the respective cytokines (n = 10 per group). P values calculated using Mann-Whitney U-tests.Figure 2Data expressed as median and interquartile range of the fold change compared with day 1 (before vaccination) (n = 10 per group). p-values calculated using repeated measures two-way analysis of variance (ANOVA, time and interaction terms) on log transformed data. Day 6 was the endotoxemia experiment day.

Conclusions {#Sec5}
===========

Gamma-irradiated BCG does not modulate the innate immune response *in vivo* in humans and is therefore unlikely to represent an effective treatment option to restore immunocompetence in patients with sepsis-induced immunoparalysis.
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